All Massachusetts General Hospital articles
-
NewsSimulation model shows potential affordability of preventative HIV therapy for infants
A type of cost-effective HIV neutralizing antibodies was evaluated to prevent the viral infection in infants during breastfeeding in high HIV prevalance countries. This treatment option is comparatively cheaper and has high clinical impacts in high HIV burden settings to achieve global elimination.
-
NewsNew therapy may effectively control HIV in Uganda
Clinical trials showed an effective antiviral drug, known as lenacapavir, against HIV in Uganda, and has also been tested for drug resistance in different subtype strains.
-
NewsTB or not TB? A new clinician decision support tool for tuberculosis
A risk assessing tool was recently developed to evaluate the likelihood of tuberculosis (TB) infections using previous patient data with or without TB. Such clinical decision support tool would allow safer and more efficient patient deisolation procedures and ensure smoother clinician workflows.
-
NewsUC San Diego to lead data hub of CDC-funded pandemic preparedness network
The CHARM Network will leverage expertise from across the country to help the nation better prepare for respiratory virus outbreaks.
-
NewsExperts develop laboratory toolkit for patients with viral hemorrhagic fevers such as Marburg virus disease
New resource provides guidance for healthcare facilities to perform basic laboratory testing in a safe and effective manner for patients at risk for Viral Hemorrhagic Fevers.
-
NewsLarge-scale study will seek to unearth causes of persistent symptoms of Lyme disease
Researchers have received $20.7 million grant to try to answer some of the most vexing questions around chronic Lyme disease, following patients from their earliest diagnosis to find out why some go on to develop debilitating symptoms later on.
-
NewsStudy identifies protein that helps COVID-19 virus evade immune system
Discovery of a new viral evasion mechanism, and of a monoclonal antibody that subverts it, is an advance in immunotherapy that offers the prospect of effective host-directed treatment to combat infections.
-
NewsGut microbe could hold a key to help people benefit from healthy foods
In a study involving 50,000+ individuals from around the world, higher gut levels of Blastocystis, a single-celled organism commonly found in the digestive system, were linked to more favorable indicators of health.
-
NewsScientists link certain gut bacteria to lower heart disease risk
Researchers have identified specific species of bacteria that consume cholesterol in the gut and may help lower cholesterol and heart disease risk in people.
-
NewsExperts warn climate change will fuel spread of infectious diseases
A team of infectious diseases experts called for more awareness and preparedness in the medical field to deal with the impact of climate change on the spread of diseases. Their article, published in JAMA, raises the alarm about the emergence and spread of harmful pathogens. The authors ...
-
NewsB cell deficient patients gain protective T cell immunity after SARS-CoV-2 vaccination, infection
Researchers found that vaccinated B cell-deficient individuals had significantly reduced risk of moderate and severe disease in comparison to those who were not vaccinated, despite an absence of anti-spike antibody responses.
-
NewsOne in five patients experience rebound COVID after taking Paxlovid, new study finds
While Paxlovid remains a ‘life-saving drug,’ researchers found that patients experiencing virologic rebound after treatment may remain contagious.
-
NewsEngineered E. coli delivers therapeutic nanobodies to the gut
A genetically modified beneficial strain of bacteria blocks intestinal inflammation in a preclinical model of inflammatory bowel disease and has the potential to treat intestinal-based diseases.
-
NewsResearchers find SARS-CoV-2 Omicron BA.2 subvariant less severe than earlier variants
team led by investigators at Massachusetts General Hospital (MGH) has determined that the SARS-CoV-2 Omicron BA.2 subvariant is less severe than the previous Delta variant and less severe to an even greater extent than the original Omicron variant.